SCHEDULE 13G/A: BlackRock Amends Stake in Celldex Therapeutics, Disclosing 7.3% Beneficial Ownership

BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, revealing a 7.3% beneficial ownership stake in Celldex Therapeutics, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 4,819,293 shares of Celldex Therapeutics, Inc. common stock.
• This represents 7.3% of the total outstanding common stock of Celldex Therapeutics, Inc.
• The filing date for the event requiring this statement was March 31, 2025.
• BlackRock holds sole voting power over 4,742,827 shares and sole dispositive power over 4,819,293 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Celldex Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive institutional investment by BlackRock, which can be viewed positively as a vote of confidence. However, it provides no new operational or financial performance data for Celldex Therapeutics itself, so the sentiment is primarily neutral to slightly positive due to the institutional backing.

Positives

• BlackRock's significant stake (7.3%) indicates a notable institutional investment in Celldex Therapeutics, potentially signaling confidence in the company's long-term prospects.
• The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of influencing control, suggesting a passive investment strategy.

Negatives

• The document does not contain any negative financial or operational information about Celldex Therapeutics, Inc. as it is a disclosure of ownership by an institutional investor.

Risks

• The document itself does not detail risks related to Celldex Therapeutics' operations or financial health, as it is a Schedule 13G filing focused on ownership disclosure.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Celldex Therapeutics' future performance or BlackRock's future investment intentions beyond the passive nature of the current holding.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing indicates continued institutional interest in the biotechnology or pharmaceutical sector, specifically in companies like Celldex Therapeutics, which is likely a clinical-stage or commercial-stage biopharmaceutical company. Large asset managers like BlackRock often hold significant stakes across various industries as part of diversified investment strategies.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, indicating a passive investment by a large institutional investor. It does not provide specific financial results for Celldex Therapeutics to compare against industry benchmarks.
• A 7.3% stake by a major asset manager like BlackRock is a significant position, though not uncommon for large funds holding diversified portfolios. For example, other major asset managers like Vanguard or State Street often hold similar or larger passive stakes in numerous publicly traded companies as part of their index or ETF offerings.
• The filing explicitly states that no single underlying BlackRock entity holds more than 5% of Celldex Therapeutics' common stock, which is typical for large diversified funds managing assets for multiple clients.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by BlackRock may be viewed positively by existing shareholders, potentially signaling institutional confidence and stability.
• Management: Awareness of a large, passive institutional investor like BlackRock may influence management's focus on long-term value creation, though BlackRock explicitly states it is not seeking to influence control.

Next Steps

• No specific future actions or milestones for Celldex Therapeutics are mentioned in this filing. BlackRock will continue to monitor its investment and file amendments if its ownership percentage changes significantly (e.g., crosses 10% or drops below 5%).

Key Dates

Keywords

Celldex Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, CDX